Jennifer J Rhodes
CIK 1568249 · EVP, CHIEF LEGAL OFFICER, SEC · last filed 2026-03-26
Jennifer J Rhodes is an EVP, CHIEF LEGAL OFFICER, SEC who has filed 43 SEC Form 4 insider transactions across 4 companies since 2014. The most recent filing, for ACAD, was dated Mar 26, 2026. Across all open-market trades the lifetime net is −$2.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $319.0K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$319.0K
4
43
-$2.44M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ACAD | EVP, CHIEF LEGAL OFFICER, SEC | 15,124 | $21.09 | $319.0K | -$245.0K | 5 | 2026-03-26 |
| Elicio Therapeutics, Inc. (ANGN) Delisted | See Remarks | 30,399 | $10.00 | $304.0K | -$62.4K | 15 | 2022-03-04 |
| Adamas Pharmaceuticals Inc (ADMS) Delisted | CBO, GC & Compliance Officer | 63,114 | $8.22 | $518.8K | -$106.0K | 13 | 2019-06-21 |
| MEDIVATION, INC. (MDVN) Delisted | GC & Corporate Secretary | 11,090 | — | — | -$2.03M | 10 | 2015-03-17 |
Recent Filings
43 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-26 | ACAD | Mixed | +3,671 | -$82.5K | EDGAR |
| 2026-03-10 | ACAD | Grant (A) | — | $0 | EDGAR |
| 2026-02-10 | ACAD | Mixed | +5,994 | -$162.5K | EDGAR |
| 2025-03-26 | ACAD | Grant (A) | — | $0 | EDGAR |
| 2024-02-08 | ACAD | Grant (A) | — | $0 | EDGAR |
| 2022-03-04 | Elicio Therapeutics, Inc. (ANGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-12-15 | Elicio Therapeutics, Inc. (ANGN) Delisted | Sell (S) | −451 | -$1.1K | EDGAR |
| 2021-11-16 | Elicio Therapeutics, Inc. (ANGN) Delisted | Sell (S) | −433 | -$1.9K | EDGAR |
| 2021-10-15 | Elicio Therapeutics, Inc. (ANGN) Delisted | Sell (S) | −430 | -$3.7K | EDGAR |
| 2021-09-15 | Elicio Therapeutics, Inc. (ANGN) Delisted | Sell (S) | −430 | -$4.6K | EDGAR |